

23. Hosaka M, Mimura A, Asayama K, Ohkubo T, Hayashi K, Kikuya M, et al. Relationship of dysregulation of glucose metabolism with white-coat hypertension: the Ohasama study. *Hypertens Res* 2010;33:937-43.
24. Martin CA, Cameron JD, Chen SS, McGrath BP. Two hour glucose post loading: a biomarker of cardiovascular risk in isolated clinic hypertension. *J Hypertens* 2011;29:749-57.
25. Mancia G, Bombelli M, Faccchetti R, Madotto F, Quartu-Trevano F, Grassi G, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. *J Hypertens* 2009;27:1672-78.
26. Franklin SS, Thijss L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. *Hypertension* 2013;61:964-71.
27. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. *J Hypertens* 2007;25:2193-8.
28. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. *Am J Hypertens* 2011;24:52-8.
29. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. *J Hypertens* 2008;26:1715-25.
30. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet* 2010;375:938-48.
31. Hashimoto T, Kikuya M, Ohkubo T, Satoh M, Metoki H, Inoue R, et al. Home blood pressure level, blood pressure variability, smoking, and stroke risk in Japanese men: the Ohasama study. *Am J Hypertens* 2012;25:883-91.
32. Metoki H, Ohkubo T, Kikuya M, Asayama K, Inoue R, Obara T, et al. The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker. *J Hypertens* 2012;30:1478-86.
33. Imai Y, Ohkubo T, Hozawa A, Tsuji I, Matsubara M, Araki T, et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. *J Hypertens* 2001;19:179-85.
34. Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA. A pharmacist-led, American Heart Association Heart360 web-enabled home blood pressure monitoring program. *Circ Cardiovasc Qual Outcomes* 2013;6:157-63.
35. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. *Ann Intern Med* 2013;159:185-94.
36. Imai Y, Ohkubo T, Kikuya M, Hashimoto J. Practical aspect of monitoring hypertension based on self-measured blood pressure at home. *Intern Med* 2004;43:771-8.
37. Edmonds D, Foerster E, Groth H, Greminger P, Siegenthaler W, Vetter W. Does self-measurement of blood pressure improve patient compliance in hypertension? *J Hypertens Suppl* 1985;3:S31-4.
38. Omvik P, Gerhardsen G. The Norwegian office-, home-, and ambulatory blood pressure study (NOHA). *Blood Press* 2003;12:211-9.
39. Marquez-Contreras E, Martell-Claras N, Gil-Guillem V, de la Figuera-Von Wichmann M, Casado-Martinez JJ, Martin-de Pablos JL, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. *J Hypertens* 2006;24:169-75.
40. Halme L, Vesalainen R, Kaaja M, Kantola I; HOrne MEasurERment of blood pressure study group. Self-monitoring of blood pressure promotes achievement of blood pressure target in primary health care. *Am J Hypertens* 2005;18:1415-20.
41. Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. *J Clin Hypertens (Greenwich)* 2006;8:174-80.
42. McManus RJ, Mant J, Roalfe A, Oakes RA, Bryan S, Pattison HM, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. *BMJ* 2005;331:493.
43. Verberk WJ, Kroon AA, Lenders JW, Kessels AG, van Montfrans GA, Smit AJ, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: A randomized, controlled trial. *Hypertension* 2007;50:1019-25.
44. Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. *J Hypertens* 2013;31:455-67; discussion 467-8.

## Book review

### **Therapeutic Guidelines: Endocrinology. Version 5.**

Melbourne: Therapeutic Guidelines Limited; 2014

419 pages

Electronic version also available

The strength of this guideline is its concise and yet thorough approach to the management of the more common endocrinological conditions. For example, strategies for the different types of diabetes are explained in great detail. The guidance for diabetic ketoacidosis and hyperosmolar hyperglycaemia is excellent. The numerous tables provided throughout the book are useful and easy to read.

However, there are areas of weakness. There are too many cross references throughout the book, making it difficult to read in parts. Reference to further

information in the electronic version of the Therapeutic Guidelines, eTG, is common. This is problematic as not every user has access to the electronic version. I do think a guide needs to be able to stand alone.

The recommendations about blood glucose monitoring are too vague and generalised. Also, the advice on sunlight exposure for patients with vitamin D deficiency lacks detail.

Despite some shortcomings, overall I think this book is excellent. I like its pocket size format, and the treatment recommendations are detailed, practical and easy to follow. I recommend this endocrinology guide to health practitioners working in a hospital or in general practice.

**Heinz Tilienius**

GP  
Melbourne

